MEI Pharma winds down cancer drug program outside Japan, shares slip
Brief: MEI Pharma Initiates Strategic Realignment
Brief: MEI Pharma And Kyowa Kirin Announce Discontinuation Of Zandelisib Development Outside Of Japan
Brief: Kyowa Kirin And MEI Pharma Announce Topline Data From Phase 2 MIRAGE Study Evaluating Zandelisib In Patients With Indolent B-Cell Non-Hodgkin's Lymphoma In Japan
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
MEI Pharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: MEI Pharma Reports First Quarter Fiscal Year 2023 Results
Advisory: Alert wrongly tagged to MEI Pharma withdrawn
Advisory: Alert wrongly tagged to MEI Pharma withdrawn
MEI Pharma Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: MEI Pharma Announces Changes To Board Of Directors
MEI Pharma Inc reports results for the quarter ended in June - Earnings Summary
MEI Pharma Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
MEI Pharma Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: MEI Pharma, Kyowa Kirin Announce Publication Of Data From Phase 1B Clinical Study Of Zandelisib
U.S. RESEARCH ROUNDUP- Brunswick, Hasbro, Seaworld Entertainment
Brief: MEI Pharma Inc Says Daniel Gold, Chief Executive Officer, Notified Drazba That His Employment Will Continue Beyond June 30, 2022
Brief: MEI Pharma Appoints Human Resources Executive Anne Frese As Chief People Officer